摘要
目的:探讨奥氮平对儿童期首发精神分裂症的临床疗效和安全性。方法:对60例年龄<14岁首次发病患儿用奥氮平治疗8周,以阳性和阴性症状量表(PANSS)评定临床疗效,以副反应量表(TESS)和实验室监测评定安全性;于基线时,实验第1、2、4、6、8周末分别评定各量表。统计方法为描述性分析和配对t检验。结果:60例患儿基本痊愈30%(18/60),显著进步30%(18/60),好转23.3%(14/60)和无效10%(6/60)。PANSS总分及各分量表分治疗前后比较均有显著性差异(P<0.01)奥氮平对阳性、阴性症状以及一般精神病性症状均有良好疗效,无严重不良反应。结论:奥氮平能缓解儿童期首发精神分裂症的精神病性症状,疗效好,安全性高。
Objective:To evaluate the efficacy and safety of Olanzapine in the first -episode Schizophrenia. Methods :60 pa- tients with oratory tests were used to assess the adverse effects( age 〈 14 years) were included in the 8 week open clinical study. The positive and Negative syndrome scale (PANSS) was used to evaluate the severity and the improvement of mental symptoms. The Treat- ment Emergent Side Effect Scale (TESS) and lab treatment of childhood patients with first -episode Schizophrenia, Scales were evalu- ated at baseline and the end of week 1 ~2 ~4 ~6~8, Descriptive analysis and paired t -test were performed in statistical analysis. Results: 60 valid cases were collected among the 60 patients30.0% met the criteria of complete relief, 30.0% significantly improved, 23.3% improved and 10.0% got no change significant olifferenees existed in total PANSS scores and factor scores of PANSS after 8 week treat- ment of Olanzapine, Olanzapine showed good effect on the positive, negative as well as general psychopathoiogical symptoms of child- hood patients with first - episode Schizophrenia. No serous act verse events were found during the treatment. Conclusions: This study suggests that Olanzapine is an effective and safe antipsyehotie in the treatment of childhood patients with first - episode Schizophrenia.
出处
《中国民康医学》
2010年第7期821-822,824,共3页
Medical Journal of Chinese People’s Health